Moreover, when Trop-2 expression levels were increased in MDA-MB-231, this previously less-responsive tumor was rendered more sensitive to SG therapy in vivo, as evidenced by tumor regressions and significantly improved survival benefit, which were greater than those achieved with irinotecan treatment. Here, TACSTD2 is linked to neoplasm.